420 Magazine Background

Ajulemic Acid: Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials

420 News

New Member
Summer Burstein

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, 01605 Worcester, MA


Abstract

Ajulemic acid (CT-3, IP-751,1',1'-dimethylheptyl-Δ8 acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects.


Source: Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials
 

ohmeded

New Member
Re: Ajulemic Acid: Synthesis, Proof of Principle, Toxicity Studies, and Clinical Tria

Do you know the current status of development of ajulemic acid?
 
Top Bottom